Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02990013 · ClinicalTrials.gov registry record · Early Phase 1
AvenovaTM as a Sterile Skin Preparation Agent
A Early Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT02990013: Completed Early Phase 1 study, sponsored by University of Miami.
NCT02990013 is a Early Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 21 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02990013, a Early Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
Aim 1: To determine in vivo capability of AvenovaTM against common cutaneous microbial biome on human skin Aim 2: To compare to povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol against AvenovaTM as a sterile skin agent
Primary Outcome
Growth or no growth of bacteria in the thioglycollate broth will be noted for the control and each quadrant after cleansing with the 4 agents listed above.
Interventions
- DEVICE Avenova
- DRUG Povidone-iodine 5% solution
- DRUG 4% chlorhexidine
- DRUG Isopropyl alcohol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2019-12-20 |
| Phase | Early Phase 1 |
What the finished NCT02990013 record still lists
NCT02990013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 4 interventions - of which Avenova is the first listed.
NCT02990013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02990013 about?
NCT02990013 is a clinical study titled "AvenovaTM as a Sterile Skin Preparation Agent". Aim 1: To determine in vivo capability of AvenovaTM against common cutaneous microbial biome on human skin Aim 2: To compare to povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol against AvenovaTM as a sterile skin agent
What is the current status of trial NCT02990013?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2018-12-01. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT02990013?
The interventions under investigation include: Avenova (DEVICE), Povidone-iodine 5% solution (DRUG), 4% chlorhexidine (DRUG), Isopropyl alcohol (DRUG).
Who is sponsoring clinical trial NCT02990013?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02990013's enrollment target sits among peer trials
21 1130th of 2000 higher than 845 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI